HWM
RXRX icon

HB Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

HB Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16,100
Closed -$106K – 1110
2024
Q3 		$106K Sell
16,100
-63,985
-80% -$459K ﹤0.01% 926
2024
Q2 		$601K Buy
+80,085
New +$698K 0.01% 491

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

HB Wealth Management's RXRX Position: Q4 2024 in Review

HB Wealth Management sold out of Recursion Pharmaceuticals (RXRX) in Q4 2024, closing a stake of 16,100 shares — an estimated $106K sold.

HB Wealth Management first reported a position in RXRX in Q2 2024 and held it in 2 quarters. The position peaked at $601K in Q2 2024. 316 funds tracked by Wall St. Rank hold RXRX as of Q4 2024.

  • HB Wealth Management reported no remaining Recursion Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • HB Wealth Management sold 16,100 Recursion Pharmaceuticals shares in Q4 2024, an estimated $106K.
  • HB Wealth Management first reported a position in Recursion Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • HB Wealth Management's Recursion Pharmaceuticals position peaked at $601K in Q2 2024.
  • 316 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2024.

Based on HB Wealth Management's 13F filing for Q4 2024, filed 15 Jan 2025.